table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderateCOVID-19 severe or critically
COVID 19 hospitalizedCOVID-19 mild to moderateCOVID-19 severe or critically
neutralizing antibody ITAC
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) ACTIV-3 ...
bamlanivimab monotherapy ACTIV-3/TICO LY-CoV555
casirivimab/imdevimab (Ronapreve) RECOVERY ... Somersan-Karakaya ...
cilgavimab and tixagevimab (Evusheld) ACTIV-3/TICO ...
equine polyclonal antibodies INM005 Lopardo
sotrovimab (Xevudy; VIR-7831) ACTIV-3/ TICO ...

2 studies excluded by filtering options 0

9481 Kim, 2022 000selection pending
10191 Chen, 2022 0100selection pending

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons